Business Context and Reporting Period
Company: SeaStar Medical Holding Corporation (ICU)
Filing Type: Form 8-K (Current Report)
Reporting Date: July 10, 2024 (Event Date); July 11, 2024 (Closing Date)
Context: The Company, an emerging growth company incorporated in Delaware, announced the entry into a Material Definitive Agreement for a Registered Direct Offering and a concurrent Private Placement. The offering closed on July 11, 2024.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than periodic operating results. Key transaction metrics include:
- Gross Proceeds: Approximately $10.0 million.
- Securities Issued:
- 947,868 shares of Common Stock.
- Common Warrants to purchase up to 947,868 shares of Common Stock.
- Offering Price: $10.55 per share (combined price for one share and one warrant).
- Warrant Terms:
- Exercise Price: $10.55 per share.
- Term: 5 years from issuance.
- Immediately exercisable.
- Placement Agent Fees:
- Cash Fee: 7.0% of gross proceeds.
- Warrant Fee: Warrants to purchase 66,351 shares (7.0% of shares placed).
- Placement Agent Warrant Exercise Price: $13.1875 per share (125% of offering price).
Use of Proceeds: General corporate purposes, including working capital, capital expenditures, and repayment of certain indebtedness.
Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide specific values for revenue, profit, cash flow, margins, or current debt levels. It only states an intent to use proceeds for debt repayment.
Material Changes Versus Prior Period
This 8-K filing reports a discrete capital event and does not provide comparative financial data (e.g., quarter-over-quarter or year-over-year) for operating metrics. The material change is the increase in equity capital and the issuance of new warrants.
Guidance, Outlook, Risks, and Contingencies
- Management Commentary: The Company plans to utilize net proceeds for general corporate purposes, specifically highlighting working capital, capital expenditures, and debt repayment.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from expectations due to risks related to closing conditions, research and product development processes, and other factors detailed in the Company's Form 10-K and prospectus supplement.
- Contingencies:
- Fundamental Transactions: In the event of a merger, acquisition, or similar fundamental transaction, warrant holders are entitled to receive the consideration they would have received had they exercised immediately prior to the transaction. Alternatively, the Company may repurchase warrants at their Black Scholes Value within 30 days of such a transaction.
- Registration Rights: The Company agreed to register the shares underlying the Common Warrants within 30 days of the Purchase Agreement date.
Important Facts for Investor Verification
- Verify the exact net proceeds after deducting the 7.0% cash fee and other offering expenses.
- Confirm the specific amount of indebtedness intended to be repaid with the proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination provisions.
- Monitor the Company's ability to register the warrant shares within the required 30-day window.
- Assess the dilution impact of the 947,868 new shares and the potential exercise of 1,014,219 total warrants (947,868 Common Warrants + 66,351 Placement Agent Warrants).